Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8776452 | 0.89 | CYP1A2 (0.41) | CYP1A2ARPDE10ANPC1TDP1 | |
| SCHEMBL3788033 | 0.86 | CYP1A2 (0.46) | CYP1A2ARPDE10ANPC1TDP1 | |
| SCHEMBL8777210 | 0.86 | CYP1A2 (0.36) | CYP1A2ARPDE10ANPC1KDR | |
| SCHEMBL8776597 | 0.84 | CYP1A2 (0.39) | CYP1A2ARPDE10ANPC1TDP1 | |
| SCHEMBL8775777 | 0.83 | CYP1A2 (0.41) | CYP1A2ARPDE10ATDP1CYP2A6 | |
| SCHEMBL8776451 | 0.83 | CYP1A2 (0.40) | CYP1A2ARPDE10ANPC1KDR | |
| SCHEMBL8777080 | 0.83 | CYP1A2 (0.48) | CYP1A2PDE10ANPC1CYP2A6KDR | |
| SCHEMBL8777078 | 0.83 | MBNL1 (0.40) | CYP1A2ARPDE10ANPC1TDP1 | |
| SCHEMBL8776881 | 0.82 | CYP1A2 (0.50) | CYP1A2PDE10ANPC1TDP1KDM4E | |
| SCHEMBL8776938 | 0.82 | PDE10A (0.51) | CYP1A2PDE10ANPC1TDP1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012069652-A2 | FUNGICIDE MIXTURES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-05-31 | — | — | WO | disclosed |
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2010136475-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | NAT1, NQO2, NOX1 | CYP1A2 18/4885AR 3869/4885PDE10A 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.